Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ever external funding round led by Thrive Capital, the startup said on Monday.

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

Demis Hassabis of Google DeepMind predicts AI can end all diseases soon. He says AI can drastically cut drug development time ...

Since its launch, Isomorphic Labs has focused on using AI to model biological processes and accelerate drug discovery. The company co-developed AlphaFold 3 with Google DeepMind, an AI model ...

The technology is genuinely useful for scientific discovery, but its applications are less dramatic than you might think.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Isomorphic Labs, the drug discovery start-up spun out of Google’s DeepMind artificial intelligence unit ...

Perplexity AI CEO Arvind Srinivas lauded Google DeepMind CEO Demis Hassabis as a 'genius,' advocating for providing him ample ...

Google-Backed AI Drug Discovery Startup Raises $600 Million (Reuters) - Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...

which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ever external funding round led by Thrive Capital, the startup said on Monday. Google ...

In a move that could accelerate and reshape therapeutic development, Google DeepMind has launched TxGemma, a suite of open AI models designed to make drug discovery faster, smarter, and more ...